Financials data is unavailable for this security.
View more
Year on year PTC Therapeutics Inc had revenues fall -13.97% from 937.82m to 806.78m, though the company grew net income from a loss of 626.60m to a smaller loss of 363.30m.
Gross margin | 96.87% |
---|---|
Net profit margin | 33.55% |
Operating margin | 45.86% |
Return on assets | 26.76% |
---|---|
Return on equity | -- |
Return on investment | 36.33% |
More ▼
Cash flow in USDView more
In 2024, PTC Therapeutics Inc increased its cash reserves by 30.32%, or 185.03m. Cash Flow from Financing totalled 255.87m or 31.71% of revenues. In addition the company used 107.69m for operations while cash from investing totalled 44.18m.
Cash flow per share | 7.85 |
---|---|
Price/Cash flow per share | 6.07 |
Book value per share | -2.34 |
---|---|
Tangible book value per share | -4.88 |
More ▼
Balance sheet in USDView more
Current ratio | 3.89 |
---|---|
Quick ratio | 3.85 |
Total debt/total equity | -- |
---|---|
Total debt/total capital | 1.08 |
More ▼